Full Text
Impact of European Medicines Agency (EMA) Clinical Trial Transparency Policies on Health Technology Assessment (HTA) Decisions In the UK

Abstract

Authors

S Cocklin S Papanicolaou C Jones

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×